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Background: Graves’ disease, a well-known cause of hyperthyroidism, is an autoimmune disease with multi-system
involvement. More prevalent among young women, it appears as an uncommon cardiovascular complication during
pregnancy, posing a diagnostic challenge, largely owing to difficulty in detecting the complication, as a result of a low
index of suspicion of Graves’ disease presenting during pregnancy. Globally, cardiovascular disease is an important
factor for pregnancy-related morbidity and mortality. Here, we report a case of Graves’ disease detected for the first
time in pregnancy, in a patient presenting with bi- ventricular heart failure, severe pulmonary hypertension and
pre- eclampsia. Emphasis is placed on the spectrum of clinical presentations of Graves’ disease, and the importance
of considering this thyroid disorder as a possible aetiological factor for such a presentation in pregnancy.
Case presentation: A 30-year-old Bangladeshi-Bengali woman, in her 28th week of pregnancy presented with severe
systemic hypertension, bi-ventricular heart failure and severe pulmonary hypertension with a moderately enlarged
thyroid gland. She improved following the administration of high dose intravenous diuretics, and delivered a
premature female baby of low birth weight per vaginally, twenty four hours later. Pre-eclampsia was diagnosed on
the basis of hypertension first detected in the third trimester, 3+ oedema and mild proteinuria. Electrocardiography
revealed sinus tachycardia with incomplete right bundle branch block and echocardiography showed severe
pulmonary hypertension with an estimated pulmonary arterial systolic pressure of 73 mm Hg, septal and anterior
wall hypokinesia with an ejection fraction of 51%, grade I mitral and tricuspid regurgitation. Thyroid function tests
revealed a biochemically hyperthyroid state and positive anti- thyroid peroxidase antibodies was found.
99mTechnetium pertechnetate thyroid scans demonstrated diffuse toxic goiter as evidenced by an enlarged thyroid
gland with intense radiotracer concentration all over the gland. The clinical and biochemical findings confirmed the
diagnosis of Graves’ disease.
Conclusions: Graves’ disease is an uncommon cause of bi-ventricular heart failure and severe pulmonary
hypertension in pregnancy, and a high index of clinical suspicion is paramount to its effective diagnosis and
treatment.
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Figure 1 Diffusely enlarged thyroid gland (indicated by arrow)
in a 30-year-old female.
Sabah et al. BMC Research Notes 2014, 7:814 Page 2 of 5
http://www.biomedcentral.com/1756-0500/7/814Background
Case report
An autoimmune disease with female predilection, Graves’
disease (GD) is the most common cause of hyperthyroid-
ism, and is associated with multisystem involvement.
Chiefly characterized by a diffuse goitre and features of
thyrotoxicosis, it may also be accompanied by an infiltra-
tive orbitopathy, ophthalmopathy and occasionally infiltra-
tive dermopathy. Due to the autoimmune nature of GD,
and given that pregnancy is a state of immunosuppression,
thyrotoxic symptoms generally show a regression as the
duration of pregnancy progresses. This can be explained
by the diminished functions of both T-cells and B-cells
under the influence of local placental factors and regula-
tory T cells. Globally, cardiovascular disease is an import-
ant factor for pregnancy-related morbidity and mortality,
and complicates 1- 4% of all pregnancies [1,2]. In addition
to maternal mortality, cardiovascular diseases are respon-
sible for approximately 30% of all deaths globally [3,4].
GD is not a common presentation of cardiovascular
complication in pregnancy. We report here a case of bi-
ventricular heart failure, severe pulmonary and systemic
hypertension and pre-eclampsia in pregnancy due to GD.
Case presentation
This 30-year-old Bangladeshi-Bengali female in her 28th
week of pregnancy was admitted to Dhaka Medical College
Hospital with shortness of breath and raised blood pres-
sure (BP - 160/100 mm of Hg). She had no prior history of
hypertension. The following day she was transferred to car-
diology owing to increased dyspnoea and altered level of
consciousness. On initial assessment she was cyanosed and
tachypnoeic with a respiratory rate of 50 breaths per min
and blood pressure was raised at 180/100 mm Hg; there
was significant bi-pedal oedema and bilateral pulmonary
crackles on lung ausculation. She improved with initial
treatment consisting of high doses intravenous diuretics
and delivered a premature female baby of low birth weight
(weight- 1.5 kg) per vaginally, twenty four hours later.
Upon further evaluation, a moderately enlarged thyroid
gland was detected. The goitre was diffuse, non-tender
and mobile, with no features of compression, thrills or
bruits (Figure 1). She had tachycardia (pulse132/min) and
a regular, high volume pulse. However, there were no
postural tremors, lid retraction, exophthalmos or other
features of thyroid eye disease. Pulse pressure was wide (80
mm Hg). She had features of bi-ventricular heart failure
with pulmonary hypertension, as evidenced by dependent
oedema, raised jugular venous pressure, left ventricular
gallop, bilateral basal lung crackles, and prominent pul-
monary component of second heart sound on palpation
and auscultation, with left parasternal heave; liver was en-
larged and tender. Haemogram, serum electrolytes, serum
creatinine and random blood sugar were within normallimit. Urine routine microscopy showed mild proteinuria
with pus cells 4-5/HPF done before delivery. Electrocardi-
ography showed sinus tachycardia with incomplete right
bundle branch block and echocardiography revealed severe
pulmonary hypertension with an estimated pulmonary
arterial systolic pressure of 73 mm Hg, mild pericardial
effusion (7 mm posteriorly), grade I mitral regurgitation
(MR) & tricuspid regurgitation (TR), septal and anterior
wall hypokinesia and fair left ventricular systolic function
with an ejection fraction of 51%. Thyroid function tests
revealed biochemically hyperthyroid state (Free T4- 4.26
ng/dl; Normal 0.71- 1.85 ng/dl and thyroid stimulation
hormone [TSH] <0.015 uIU/ml; Normal 0.3 – 0.5 mIU/l).
She had positive anti thyroid peroxidase antibodies (2107
μ/ml; Normal ≤15 μ/ml) and negative TSH receptor
antibody. 99mTechnetium pertechnetate thyroid scans
confirmed a diffuse toxic goitre as evidenced by enlarged
thyroid gland with intense radiotracer concentration all over
the gland. Thus the clinical, biochemical and radiological
features were consistent with Graves’ thyrotoxicosis. Pre-
eclampsia was diagnosed on the basis of hypertension
first detected in the third trimester, significant oedema
and mild proteinuria. She responded to intravenous di-
uretics. Her thyroid hyperactivity was controlled with
carbimazole 45 mg/day and propranolol 40 mg/day in
divided doses, and blood pressure control following de-
livery was achieved with losartan potassium 50 mg/day.
Her child also made a healthy recovery and they are
both on regular follow up with the Cardiologist, Endo-
crinologist and Paediatrician.
Discussion
Graves’ disease, named after Robert J. Graves was first de-
scribed in 1825 by Dr. Caleb Hillier Parry [5,6]. Known in
Europe as von Basedow’s disease [7], it is an autoimmune
Table 1 Potential maternal and fetal complication in
uncontrolled hyperthyroidism
Maternal Fetal
1. Pregnancy induced hypertension 1. Neonatal hyperthyroidism
2. Pre-eclampsia 2. Intrauterine growth retardation
3. Preterm delivery 3. Small-for-gestational- age
4. Congestive heart failure 4. Prematurity
5. Thyroid storm 5. Stillbirth
6. Increased or recurrent miscarriage 6. Increased perinatal mortality
7. Placenta abruption
8. Infection
9. Increased maternal mortality
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the 40- to 60-year age group and female to male ratio of
5–10:1 [8].
In this case, the young age of onset of disease (at 30
years) and high levels of anti-thyroid peroxidase anti-
bodies indicate the genetic and epigenetic factors in-
volved in the pathogenesis of GD. Immunochip genetic
association analyses have identified 30 single-nucleotide
polymorphisms in several genes significantly associated
with the young age of onset (AO) GD, i.e. onset <30 years
of age, including major histocompatibility complex class I
and class II genes, BTNL2, NOTCH4, TNFAIP3 and
CXCR4; most of the genes known to be associated with
adult-onset GD were also associated with Young AO GD
[9]. The epidemiology of GD is the result of complex
interactions between genetic, epigenetic and various
environmental factors. Gene- gene interactions and gene-
environment interactions (e.g. viral infection-related
production of interferon-α induced alteration in thyro-
globulin gene expression through epigenetic changes in
histone modification) are mainly accountable for the
pathogenesis. The thyroidal CD40 over expression can
augment the severity of GD but is not required for dis-
ease development; in mice, it increased the level of
thyrotropin (TSH) receptor antibodies and thyroid hor-
mone production [10-14]. In humans, it is strongly asso-
ciated with persistently high levels of post- treatment
thyroid antibodies suggesting a role in thyroid antibody
production [15]. The risk of developing GD is greatly in-
creased when two or more disease-associated alleles are
inherited together [14].
In the vast majority of cases, GD is the chief cause for
thyrotoxicosis in pregnancy. However, as both pregnancy
and hyperthyroidism are accompanied by thyroid stimu-
lation, hyperdynamic circulation and hypermetabolism,
the detection of hyperthyroidism can be challenging dur-
ing pregnancy. Biochemically, a serum TSH level lower
than the trimester-specific lower limit 0.3 mIU/L and an
elevated free T4 level greater than the normal range for
pregnancy strongly suggests coexistent hyperthyroidism;
the detection of TSH receptor antibodies virtually con-
firms the diagnosis of GD [7]. In this case, confirmation
of GD was achieved by the findings of diffuse toxic goiter
in 99m Technetium scintigraphy thyroid scans and highly
raised anti thyroid peroxidase antibodies albeit negative
TSH receptor antibody.
Severe GD is uncommon in pregnancy as it is related
with reduced fertility. For women with milder disease
who successfully conceive, hyperthyroidism endows an
increased risk of pregnancy loss and established preg-
nancy complications (Table 1) [7,16].
In this case, GD was first detected during the third
trimester of pregnancy and was complicated by the de-
velopment of bi- ventricular heart failure, owing to thesimultaneous contributions of both thyrotoxicosis and
pre-eclampsia. With a blood pressure of 180/100mmHg,
we also found a wide pulse pressure in this patient,
characteristic of hyperthyroidism. Hyperthyroidism is a
secondary cause of isolated systolic hypertension despite
low systemic vascular resistance, due to increased arter-
ial stiffness [17,18]. Cardiac output may be increased by
50 – 300% over that of normal subjects as a result of the
combined effect of increase in resting heart rate, left
ventricular contractility, ejection fraction and blood vol-
ume with a decrease in systemic vascular resistance
[19,20]. Thyroxin not only affects the heart, but also al-
ters the vascular smooth muscle and endothelial cell
function via genomic and non-genomic actions target-
ing membrane ion channels and endothelial nitric oxide
synthesis [21,22]. In addition, research evidence has re-
vealed that the Calcium/ Calmodulin- dependent kinase
IV (CaMKIV), which is a major thyroid hormone target
gene in the developing brain, plays an important role in
blood pressure regulation through the control of endo-
thelial nitric oxide synthase (eNOC) activity. There is
also a significant association between the human CaM-
KIV gene polymorphism and high diastolic blood pres-
sure among hypertensive patients [23,24]. This patient
had high diastolic blood pressure (diastolic blood pres-
sure 100 mm Hg) and there is a possibility of presence
of CaMKIV gene polymorphism in this case. Dysfunc-
tional CaMKIV, albeit not expressed in the heart, might
partake in cardiac organ damage in the context of the
hypertensive state that we found in this case [23].
It has been well established that hyperthyroidism is
associated with left ventricular dysfunction and heart fail-
ure [25]. β - adrenergic receptors in the myocardium are
under thyroid hormone regulation and are positively regu-
lated; the G- protein coupled receptor kinase GRK5 is an
important regulator in beta-adrenergic signaling [20,26,27].
There is recent emergence of evidence of GD involving
the right heart, similar to our case.One study reported that
49% of patients with primary pulmonary hypertension
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chemical and serologic evaluation [28]. Another study
revealed that pulmonary hypertension was detected echo-
cardiographically in 15 patients out of 23 patients (63%) of
hyperthyroidism [29]. Albeit unconfirmed, pulmonary
hypertension in hyperthyroidism can be postulated by the
following: 1) immune mediated endothelial damage or
dysfunction; 2) endothelial injury as a result of increased
cardiac output; 3) increased metabolism of intrinsic pul-
monary vasodilator substance (prostacyclin and nitric
oxide) [30-33]. The regression of pulmonary hypertension
following maintenance of euthyroid state may support this
mechanism.
Concordant with this patient’s finding of MR and TR
on Doppler echocardiography, atrioventricular valve re-
gurgitation has been documented to occur in hyperthy-
roidism with a high prevalence [34-36].
Conclusions
This was a unique case of GD-related bi- ventricular
heart failure, severe pulmonary hypertension and pre-
eclampsia in pregnancy. Albeit uncommon, un-explained
bi-ventricular heart failure in pregnancy may very well be
explained by Graves’ disease. Such a diagnosis requires a
high index of suspicion and subsequently specific treat-
ment should be commenced promptly in order to ensure
better outcome in such patients.
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